Gal α1-3gal-containing N-glycans in glycoprotein products derived from CHO cells

• US 8,586,356 B2
• Filed: 01/22/2009
• Issued: 11/19/2013
• Est. Priority Date: 01/22/2009
• Status: Active Grant

• Current Assignee: Momenta Pharmaceuticals Incorporated (Johnson & Johnson)
• Original Assignee: Momenta Pharmaceuticals Incorporated (Johnson & Johnson)
• Inventors: Bosques, Carlos, Murphy, Jennifer, Sarvaiya, Hetal, Washburn, Nathaniel, Liu, Cuihua, Xu, Xiao-Jin
• Primary Examiner(s): Gabel, Gail R
• Application Number:
  US12/529,109
• Publication Number:
  US 20110045496A1
• Time in Patent Office: 1,762 Days
• Field of Search: 435/7.21, 435/14, 435/69.1, 435/69.8, 435/208, 435/358, 435/362, 435/70.1, 435/96, 435/374, 436/161, 436/171, 436/173, 436/174, 436/175, 436/177, 436/63, 530/395
• US Class Current: 435/362
• CPC Class Codes: C07K 14/70521 CD28, CD152
• CPC Class Codes: C07K 2319/30 Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
• CPC Class Codes: C12P 21/005 Glycopeptides, glycoproteins
• CPC Class Codes: G01N 2400/02 involving antibodies to sugar part of glycoproteins
• CPC Class Codes: G01N 33/5308 for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
• CPC Class Codes: Y10T 436/24 Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
• CPC Class Codes: Y10T 436/25 including sample preparation
• CPC Class Codes: Y10T 436/25125 Digestion or removing interfering materials
• CPC Class Codes: Y10T 436/25375 Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]

Abstract

The present invention provides methods of evaluating CHO cells.

Claims

1. A method for screening Chinese Hamster Ovary (CHO) cells for the ability to produce a target recombinant glycoprotein comprising glycans containing a target level of terminal galactose-alpha-1-3-galactose epitopes, the method comprising:

(a) producing a target recombinant glycoprotein comprising one or more glycans by culturing CHO cells under conditions suitable for expression of the target recombinant glycoprotein by the CHO cells, wherein the CHO cells have not been genetically engineered to produce terminal alpha-galactosyl residues on glycans;

(b) treating the one or more glycans of the target recombinant glycoprotein with one or more exoglycosidases;

(c) detecting digested terminal galactose-alpha-1-3-galactose residues to thereby measure glycans containing terminal galactose-alpha-1-3-galactose residues produced by the CHO cells, and

(d) selecting the CHO cells if a target level of terminal galactose-alpha-1-3-galactose residues is measured.

2. The method of claim 1, wherein the CHO cells are in a cell culture.

3. The method of claim 2, wherein the cell culture is in a bioreactor.

4. The method of claim 1, wherein the detecting is performed on any of:

the target recombinant glycoprotein isolated from the CHO cells, peptides obtained from the target recombinant glycoprotein expressed by the CHO cells, cell surface glycans of the CHO cells, glycan preparations obtained from the CHO cells, glycan preparations obtained from the target recombinant glycoprotein expressed by the CHO cells, and combinations thereof.

5. The method of claim 1, wherein the producing step further includes the step of isolating the target recombinant glycoprotein from the CHO cells.

6. The method of claim 1, wherein the detecting step comprises use of a technique selected from the group consisting of:

chromatographic methods, mass spectrometry (MS) methods, electrophoretic methods, nuclear magnetic resonance (NMR) methods, monosaccharide analysis, fluorescence methods, UV-VIS absorbance, enzymatic methods, and combinations thereof.

7. The method of claim 1, wherein the target recombinant glycoprotein is a human therapeutic glycoprotein and the CHO cells have been transformed with a vector encoding the human therapeutic glycoprotein.

8. The method of claim 1, wherein the method comprises screening CHO cells from at least one of:

at least two different CHO strains, at least two different clonal cell populations, and at least two different samples from a cell culture in a manufacturing process train for a therapeutic glycoprotein.

9. The method of claim 1, further comprising a step of culturing the selected CHO cells to produce a therapeutic glycoprotein product.

10. The method of claim 1, wherein the method comprises screening CHO cells from two or more CHO cell populations and the method further comprises comparing the levels of glycans containing terminal galactose-alpha-1-3-galactose residues produced by the CHO cells of the two or more CHO cell populations.

11. The method of claim 1, further comprising comparing the level of glycans containing terminal galactose-alpha-1-3-galactose residues produced by the CHO cells to a reference glycoprotein sample.

12. The method of claim 1, further comprising recording the measured level of glycans containing terminal galactose-alpha-1-3-galactose residues in a print or computer-readable medium.

13. The method of claim 1, wherein the target level is a quality criterion for a pharmaceutical preparation.

14. The method of claim 1, wherein the target level is a range or value in a product specification.

15. The method of claim 1, wherein the target level is no more than 5% terminal galactose-alpha-1-3-galactose.

16. The method of claim 1, wherein detecting comprises use of a detection molecule.

17. The method of claim 1, wherein the one or more exoglycosidases are selected from the group consisting of sialidase, galactosidase, hexosaminidase, mannosidase, and fucosidase.

18. The method of claim 1, wherein the treating step comprises treating with one or more exoglycosidases for a time and under conditions suitable for the one or more exoglycosidases to cleave one or more terminal glycosidic bonds from a non-reducing end of the one or more glycans.